Psychedelic research and access in
Nebraska
Nebraska remains a no-services state for classical psychedelic access, but its statute has an important FDA-contingent nuance. Nebraska law lists psilocybin as Schedule I but excludes from that definition any pharmaceutical composition of crystalline polymorph psilocybin approved by the federal FDA.
Key Insights
- 1
Nebraska has no live psilocybin services or decriminalisation pathway.
- 2
The state has pre-positioned for possible FDA-approved crystalline polymorph psilocybin, but that is future-contingent.
- 3
Ketamine is Schedule III, and provider-level Spravato/ketamine access exists in Omaha and Lincoln.
- 4
No major classical psychedelic trial site was verified in this pass.
- 5
Nebraska is a useful state to monitor if FDA approval of a psilocybin medicine becomes imminent.
Research Snapshot
Deep reportBlossom currently tracks 7 psychedelic clinical trials with verified sites in Nebraska, including 4 active studies.
- Active trials
- 4
- Total trials
- 7
- Stakeholders
- 1
- Events
- 0
Verified state-linked study sites
Linked trial records
1 physical, 0 jurisdiction-linked
Linked state-level events
Top Compounds
- Psilocybin(5)
- Esketamine(2)
Top Study Topics
- Treatment-Resistant Depression (TRD)(4)
- Major Depressive Disorder (MDD)(1)
- Older Adults(1)
- Palliative & End-of-Life Distress(1)
Active Trial Preview
View linked trials →Access and Reimbursement
Ketamine/esketamine access; no state-regulated classical psychedelic pathwayPatient access in Nebraska is ordinary ketamine/esketamine care and research, not classical psychedelic therapy. Nebraska-specific public Medicaid coverage language for Spravato was not fully verified in this pass, but provider-level signals show Spravato and IV ketamine availability in Omaha and Lincoln through private or nonprofit clinics. Parker Neuroscience in Omaha advertises IV ketamine and Spravato, and ORIGEN Healthcare advertises in-clinic Spravato treatment.
Research signal
AvailableThis source pass did not verify a major Nebraska-based classical psychedelic clinical trial site. Nebraska's evidence environment appears more aligned with interventional psychiatry and provider-level ketamine/esketamine than with university-led psilocybin or MDMA trials.
Ketamine / esketamine
AvailablePatient access in Nebraska is ordinary ketamine/esketamine care and research, not classical psychedelic therapy. Nebraska-specific public Medicaid coverage language for Spravato was not fully verified in this pass, but provider-level signals show Spravato and IV ketamine availability in Omaha and Lincoln through private or nonprofit clinics.
No state service model
Not AvailableNo state-regulated psilocybin, MDMA or natural-medicine service model is verified for Nebraska.
Classical psychedelics
Not AvailableNebraska's most relevant policy marker is the crystalline-polymorph psilocybin carve-out in the controlled-substance statute and LB 230 history. A 2025 Judiciary Committee transcript explained that psilocybin remains Schedule I, while an FDA-approved pharmaceutical composition of crystalline polymorph psilocybin would appear in Schedule IV only upon approval.
Reimbursement / payment
LimitedNebraska has state-specific Medicaid or payer material relevant to esketamine, but current plan criteria should be rechecked before publication.
Policy and Access Timeline
State-level bills, laws, pilots, agency actions and reimbursement signals that shape real-world access.
1 Jan 2026
ActiveAgency GuidanceNebraska statute continues to list ketamine in Schedule III and psilocybin as Schedule...
Nebraska statute continues to list ketamine in Schedule III and psilocybin as Schedule I subject to the FDA-approved crystalline-polymorph exception.
NebraskaNebraska Revised Statutes Section 28-405→1 Sept 2025
ActiveLawSecondary legal analysis notes the crystalline polymorph psilocybin exception in Nebras...
Secondary legal analysis notes the crystalline polymorph psilocybin exception in Nebraska law.
NebraskaLegislative Analysis and Public Policy Association→
Regulatory Status
Nebraska remains a no-services state for classical psychedelic access, but its statute has an important FDA-contingent nuance. Nebraska law lists psilocybin as Schedule I but excludes from that definition any pharmaceutical composition of crystalline polymorph psilocybin approved by the federal FDA. It also lists ketamine in Schedule III. That exception is not a live access programme. It appears designed to avoid state-law conflict if an FDA-approved crystalline polymorph psilocybin medicine reaches market; until then, non-research psilocybin, MDMA, LSD, DMT, ibogaine and mescaline access remains unavailable under ordinary state law.
Medical Access Summary
Patient access in Nebraska is ordinary ketamine/esketamine care and research, not classical psychedelic therapy. Nebraska-specific public Medicaid coverage language for Spravato was not fully verified in this pass, but provider-level signals show Spravato and IV ketamine availability in Omaha and Lincoln through private or nonprofit clinics.###
Parker Neuroscience in Omaha advertises IV ketamine and Spravato, and ORIGEN Healthcare advertises in-clinic Spravato treatment. Those are useful access signals, but reimbursement, Medicaid acceptance and observation billing should be checked at provider and payer level before advising patients.###
Local Research Map
Verified Blossom records with coordinates in Nebraska, including trial sites, physical stakeholders and events.
Policy and Access Context
Nebraska's most relevant policy marker is the crystalline-polymorph psilocybin carve-out in the controlled-substance statute and LB 230 history. A 2025 Judiciary Committee transcript explained that psilocybin remains Schedule I, while an FDA-approved pharmaceutical composition of crystalline polymorph psilocybin would appear in Schedule IV only upon approval.###
This is a narrow pharmaceutical-readiness move rather than decriminalisation, services legalisation or a state therapeutic programme. It may matter if COMP360 or another FDA-approved psilocybin product reaches the market, but it does not change present-day access.###
Research Focus
This source pass did not verify a major Nebraska-based classical psychedelic clinical trial site. Nebraska's evidence environment appears more aligned with interventional psychiatry and provider-level ketamine/esketamine than with university-led psilocybin or MDMA trials.###
For Blossom, Nebraska should be mapped carefully: if trials appear through national sponsors, they should be linked via the trial database rather than inferred from the state's FDA-contingent statute.###
Implementation Context
Nebraska has no psilocybin services regulator, facilitator licensing, natural-medicine board or state-funded psychedelic therapy pilot. The state's implementation work is legal classification rather than service delivery.###
If an FDA-approved psilocybin medicine becomes available, Nebraska's carve-out could make state scheduling cleaner than in states that have not pre-positioned. Even then, patient access would still depend on federal approval, DEA scheduling, prescriber rules, REMS or label requirements, payer coverage and local provider willingness.###
Ecosystem Context
Omaha and Lincoln are the practical ecosystem anchors because they concentrate the visible ketamine/esketamine providers. Parker Neuroscience and ORIGEN Healthcare are examples of clinic-level access signals; Lutheran Family Services has also been described by secondary provider directories as a Lincoln Spravato access point.###
The state does not yet read as a classical psychedelic research or policy hub. Its distinctive value for readers is the FDA-contingent psilocybin scheduling detail.###
Key Milestones
Future Outlook
Nebraska's near-term outlook depends less on state reform politics than on federal pharmaceutical development. If an FDA-approved psilocybin product arrives, Nebraska has already built a statutory hook that could simplify state scheduling.###
Outside that scenario, access is unlikely to change materially. Expect ordinary ketamine/esketamine practice to continue, with reimbursement and provider availability varying by clinic and payer.###
Sources and Verification
Last updated 18 May 2026. Source links are drawn from citation annotations in the subnational report.
State-Linked Stakeholders
Organisations with verified physical locations or jurisdiction-level coverage in Nebraska.
Clinical Trials
Trial records with verified sites in Nebraska.